PlenSat is a medical device company that has developed a new approach to obesity control, “The Digestible Balloon”. The Company believes this device will provide the benefits of bariatric surgery (stomach stapling, stomach banding, gastric bypass, and gastric balloon insertion) without invasive procedures. Digestible Balloon Therapy will potentially allow the treatment of patients suffering from obesity and overweight with an easy to use and reversible technology that can be made available to the large number of patients in need.
The need for treatment is overwhelming as overweight and obesity have been shown to lead to Type 2 Diabetes and prediabetes in many patients. Weight loss and proper nutrition are key components of diabetes care, as well as being central to prevention of Type 2 Diabetes, and to the emerging concept of Type 2 Diabetes remission or reversal. (Editorial, Lancet Diabetes and Endocrinology, 7 p433, June 2019)
The concept behind Digestible Balloon Therapy is simple. Space filling devices and space constricting devices have been shown to be effective in some patients at controlling their appetite by inducing a feeling of fullness. PlenSat believes that the use of safe, easily swallowed, self inflating, self eliminating food based devices will make this therapy more widely available.
Digestible Balloons Animation
Press arrow to start
The video is a stylized representation of the designed mode of action of the device. Validation of the device is currently underway in human clinical studies.
Dr. Fred Voss received his PhD in Chemistry from the University of Colorado, Boulder in 1974. Following his PhD, Dr. Voss carried out academic research in biomedical engineering under an NIH fellowship at the University of California, San Diego for 2 years. Dr Voss has over 30 years of industry experience in the area of medical devices and therapeutics. He has been successful in establishing teams and managed all aspects of organization from R&D, QA/QC, regulatory, manufacturing. Dr. Voss was a member of the management team and the lead technical individual for an early stage cell transplant company that successfully completed an IPO.
Chief Technical Officer
Dr. Bernhard Sterling received his PhD in Biochemistry from the University of Basel in Switzerland in 1975. Following his PhD Dr. Sterling carried out 8 years of Academic research at the Max Planck Institute and the Stanford Medical Center on Human Metabolism. Dr Sterling has over 24 years of industry experience in the area of physiological structures, functions and disorders and medical devices. He was the CSO of Woolsthorpe LLC in Nashville, TN and the CSO of Optiscan Biomedical in Hayward, CA.
Executive VP Business Development
Mr. Hendrikus J. Rutten (Erik) obtained his Master of Science Chemical Technology (Polymer Science) in combination with a MBA program at the University of Twente (The Netherlands) in 1985 . Mr. Rutten has over 30 years of international experience in Business Development, R&D Management and Innovation strategy at DSM.
He had leadership positions in DSM Fine Chemicals, Coating Resins, Pharmaceuticals, Corporate R&D and Corporate Innovation Center. During the last 7 years Mr. Rutten was active in DSM’s corporate venturing arm in the USA, investing in start-ups and taking Board of Director positions in areas related to food ingredients, nano-materials, bio-based chemicals, biomedical materials, specialty coatings and cleantech. He is the CEO and Founder at Rutten Consultancy.